REGN241004C1037500
- 6.10
- -16.40-72.89%
Regeneron Pharmaceuticals Newsroom
Declining Stock and Solid Fundamentals: Is The Market Wrong About Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)?
$100 Invested In This Stock 5 Years Ago Would Be Worth $400 Today
Erste Group Downgrades Regeneron Pharmaceuticals(REGN.US) to Hold Rating
Barclays Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Maintains Target Price $1,220
Regeneron Pharma, Super Micro Computer And Global Payments Are Among Top 10 Large Cap Losers Last Week (Sept 23-Sept 27): Are The Others In Your Portfolio?
Novo Nordisk's Ozempic, Regeneron/Sanofi's Dupixent Set to Advance in Top Drug Sales
Notable Analyst Calls This Week: Microsoft, Starbucks and GM Among Top Picks
Jim Cramer on Regeneron Pharmaceuticals Inc. (REGN): 'Leerink Analysts Downgraded Regeneron To A Market Perform Hold After A Negative Eylea 2mg Biosimilar Preliminary Injunction Ruling'
Weekend Reading | Regenerative materials move towards becoming a billion-dollar giant
For a deeper understanding of how Rebirth Element has come to this day and the expected future growth.
TD Cowen Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Maintains Target Price $1,230
S&P 500 Extends Winning Streak to Third Week as Materials Sector Climbs
News Highlights: Top Company News of the Day - Friday at 1 PM ET
Regeneron Pharmaceuticals Suffers Worst Month in Two Years After Legal Setback
Express News | Regeneron Pharmaceuticals Shares up 1.9% After US FDA Approves Co and Partner Sanofi's Drug to Treat 'smoker's Lung'
Regeneron Pharmaceuticals Announces Dupixent Approved In The U.S. As The First-Ever Biologic Medicine For Patients With COPD
Express News | Dupixent® (Dupilumab) Approved in China as the First-Ever Biologic Medicine for Patients With Chronic Obstructive Pulmonary Disease (Copd)
This week in the US stock market | China's assets experience a "big carnival", goldman sachs and other major banks are all bullish! Ke Holdings surged nearly 40% during the week, with jd.com and pdd holdings rising by about 30%.
This week, the Dow Jones Industrial Average rose by 0.27% to 42175.11 points; during the same period, the S&P 500 index rose by 0.75% to 5745.37 points; the Nasdaq index rose by 1.35% to 18190.29 points during the same period.
Regeneron to Report Third Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on October 31, 2024
Wells Fargo Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Maintains Target Price $1,200
Morgan Stanley Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Maintains Target Price $1,247